Last $1.12 USD
Change Today 0.00 / 0.00%
Volume 392.7K
GERN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 05/24/13 All times are local (Market data is delayed by at least 15 minutes).

geron corp (GERN) Snapshot

Open
$1.10
Previous Close
$1.12
Day High
$1.13
Day Low
$1.09
52 Week High
09/7/12 - $2.99
52 Week Low
12/4/12 - $0.91
Market Cap
146.2M
Average Volume 10 Days
569.1K
EPS TTM
$-0.46
Shares Outstanding
130.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GERON CORP (GERN)

Related News

No related news articles were found.

geron corp (GERN) Related Businessweek News

No Related Businessweek News Found

geron corp (GERN) Details

Geron Corporation, a biopharmaceutical company, develops therapies for cancer. Its clinical development product candidate includes Imetelstat, a telomerase inhibitor, which is in Phase II clinical trials for the treatment of advanced non-small cell lung cancer, essential thrombocythemia, and multiple myeloma. The company was founded in 1990 and is based in Menlo Park, California.

105 Employees
Last Reported Date: 03/15/13
Founded in 1990

geron corp (GERN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $589.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $259.0K
Senior Vice President of Portfolio & Alliance...
Total Annual Compensation: $427.5K
Executive Vice President, General Counsel and...
Total Annual Compensation: $255.5K
Acting Head of Research and Executive Vice Pr...
Total Annual Compensation: $103.5K
Compensation as of Fiscal Year 2012.

geron corp (GERN) Key Developments

Geron Corporation Announces Executive Changes

Geron Corporation announced that Edward V. Fritzky and Thomas D. Kiley, each a Class II member of the Board of Directors and each a member of the Audit Committee of the Board, retired from the Board, effective as of May 22, 2013, the date of the company’s Annual Meeting of Stockholders. In connection with their retirement, the Board appointed director V. Bryan Lawlis, Ph.D., to the Audit Committee of the Board and Hoyoung Huh, M.D., Ph.D., to the Nominating and Corporate Governance Committee of the Board.

Geron Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2013

Geron Corporation reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported loss from operations was $11,985,000 against $18,918,000 a year ago. Net loss was $11,897,000 against $18,739,000 a year ago. Basic and diluted net loss per share was $0.09 against $0.15 a year ago. Operating Revenue was $0.765 million compared to $1.3 million for the comparable 2012 period.

Geron Corporation, Q1 2013 Earnings Call, Apr 26, 2013

Geron Corporation, Q1 2013 Earnings Call, Apr 26, 2013

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GERN:US $1.12 USD 0.00

GERN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advanced Cell Technology Inc $0.07 USD +0.0005
Athersys Inc $1.74 USD -0.07
Cytori Therapeutics Inc $2.50 USD -0.07
Neostem Inc $0.59 USD +0.02
StemCells Inc $1.83 USD -0.05
View Industry Companies
 

Industry Analysis

GERN

Industry Average

Valuation GERN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 64.6x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 30.2x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GERON CORP, please visit www.geron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.